Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure:

##STR00001##

wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.

Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure:

##STR00001##

wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.

This invention relates to compounds of general formula (I)

##STR00001##

in which R.sup.1, R.sup.2, U, V, L, M, R.sup.5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

The present technology is directed to compounds, compositions, and methods related to inhibition of ASK1. In particular, the present compounds (e.g., compounds of Formula I as defined herein) and compositions may be used to treat ASK1-mediated disorders and conditions, including, e.g., fibrotic diseases and acute and chronic liver diseases, among others.

The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed. ##STR00001##

The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed. ##STR00001##

Provided is a compound of Chemical Formula 1:

##STR00001## wherein, in Chemical Formula 1: X.sub.1 to X.sub.6 are each independently CH or N, with the proviso that at least one of X.sub.1 to X.sub.6 is N; Ar.sub.1 to Ar.sub.4 are each independently a substituted or unsubstituted C.sub.6-60 aryl, with the proviso that at least one of Ar.sub.1 to Ar.sub.4 is a C.sub.6-60 aryl containing deuterium as a substituent; R.sub.1 is hydrogen, deuterium, a substituted or unsubstituted C.sub.6-60 aryl, or a substituted or unsubstituted C.sub.2-60 heteroaryl containing one or more heteroatoms selected from the group consisting of N, O, and S; and n is an integer of 0 to 8,
and an organic light emitting device including the using same.

A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

The present invention provides compounds of Formula (I) which can be used as SGK inhibitors; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by SGK by administering the compounds of the invention. ##STR00001##